by
Christophe Come;
Anna Cvrljevic;
Mohd Moin Khan;
Irina Treise;
Thure Adler;
Juan Antonio Aguilar-Pimentel;
Byron B. Au-Yeung;
Eleonora Sittig;
Teemu Daniel Laajala;
Yiling Chen;
Sebastian Oeder;
Julia Calzada-Wack;
Marion Horsch;
Tero Aittokallio;
Dirk H. Busch;
Markus W. Ollert;
Frauke Neff;
Johannes Beckers;
Valerie Gailus-Durner;
Helmut Fuchs;
Martin Hrabě de Angelis;
Zhi Chen;
Riitta Lahesmaa;
Jukka Westermarck
The oncoprotein Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is overexpressed in most malignancies and is an obvious candidate target protein for future cancer therapies. However, the physiological importance of CIP2A-mediated PP2A inhibition is largely unknown. As PP2A regulates immune responses, we investigated the role of CIP2A in normal immune system development and during immune response in vivo.We show that CIP2A-deficient mice (CIP2A HOZ ) present a normal immune system development and function in unchallenged conditions. However when challenged with Listeria monocytogenes, CIP2A HOZ mice display an impaired adaptive immune response that is combined with decreased frequency of both CD4 + T-cells and CD8 + effector T-cells. Importantly, the cell autonomous effect of CIP2A deficiency for T-cell activation was confirmed. Induction of CIP2A expression during T-cell activation was dependent on Zap70 activity. Thus, we reveal CIP2A as a hitherto unrecognized mediator of T-cell activation during adaptive immune response. These results also reveal CIP2A HOZ as a possible novel mouse model for studying the role of PP2A activity in immune regulation. On the other hand, the results also indicate that CIP2A targeting cancer therapies would not cause serious immunological side-effects.